^
    Back
    Association details:
    Biomarker:CDKN2A Negative + NRAS Mutation
    Cancer:Melanoma
    Drug:Verzenio (abemaciclib) (CDK4/6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Clin Oncol
    Title:

    A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.

    Excerpt:
    One pt with CDKN2A-/- NRAS mutant melanoma had a confirmed partial response….
    DOI:
    10.1200/jco.2013.31.15_suppl.2500